TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sexual function in obese women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexual function in non-obese women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexual function in obese men
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexual function in non-obese men
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Evaluation of nutrient consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of patients FLT3 negative at diagnosis who relapse FLT3 positive
Endpoint domain: Mortality/survival
Primary endpoint: percentage of patients FLT3 positive at diagnosis who relapse FLT3 negative
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with decreased sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Success Percentage
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in disease markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in swallowing quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Aberrant Inflammatory Profiles of Activated Blood Monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative recurrence of liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Fast Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of PWID who attend Needle Syringe Programs (NSPs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of PWID who receive an HIV test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of HIV positive PWID who are referred to HIV care from NSPs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chemotherapy Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to VTE treatment recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radio graphic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of preventable medical errors or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Surface Temperature of Both Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve conduction improvement or deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with a 30% increase in total Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Treatment Intensification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-culprit Lesion Related Major Adverse Cardiac Events
Endpoint domain: Mortality/survival
Primary endpoint: Development of cardiac alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with mRS less than or equal to 1 at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Timolol area under the plasma drug concentration-time curve (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest drug concentration observed in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity measured by PHQ
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentrations of circulating oral contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparative tongue bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect-site Concentration of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentration of Serotype-Specific Pneumococcal IgG Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: liver volume calculated by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permeability of the blood brain barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects experiencing treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Time to Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Excess Double-strand DNA Break Foci Per Cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Reporting Grade 2 or 3 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: improved urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: decrease in the long term risk of stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: All cause mortality at one year after ICU discharge
Endpoint domain: Mortality/survival
Primary endpoint: Number of Molars With ICDAS Score of 3 or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICDAS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Axillary Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tolerance evaluation index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sodium balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local recurrence free survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Composite Rate of All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: AI ≥ Moderate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IFN-gamma/ Granzyme B producing CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Physical Health Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Psychological Health Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Nerve Conduction Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life differentials
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: modified American Fertility Society (mAFS) score at the posterior uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety of the Split Virion Pandemic Influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Apparent Volume of Distribution (Vd/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probable Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tobacco Abstinence at 6-months Post-partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco Abstinence at End of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in serum concentrations of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in serum concentrations of luteinizing hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in serum concentrations of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in serum concentrations of hCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With a Serious Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Global Dystonia Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine neurotransmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Usability of the FreeStyle Flash Libre glucose monitoring system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Timed Up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Tenofovir (TFV) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC TFV diphosphate (TFV-DP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global eye-gaze characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feature-specific eye-gaze characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of evaluable cancer tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-lesion temporal variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-lesion spatial variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Primary Care Physician visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Differences in Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Provider Use of Best Acts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Mean Trabecular Bone Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severe early-onset COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: post-operative acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Normalization of serum alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With tSCI Recruited Within the Specified Time Window
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Secretory flow rates measured by volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bicarbonate concentration of timed pancreatic juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maladaptive Avoidance Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: emotion-specific saccade latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: emotion-specific error rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Benzodiazepine exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of out-of-field failures
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Screened Participants That Are Eligible and Choose Participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinically acceptable blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Discharged From Rehabilitation by Day Four
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: relapse or recurrent rate of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of patients with CDEISm < 6 and decrease in CDEISm ≥ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean production cost of the surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of FCR recipients free from immunosuppression without biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pattern and amount of analgesics consumed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Premature Discontinuation of Study Drug Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: ECG evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sperm DNA fragmentation Index (DFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Benefit/harm of school doctors' routine health checks
Endpoint domain: Adverse events/effects
Primary endpoint: Markers of ER stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum observed drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximum drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration of AFC estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Reported Nausea at 30 Minutes Post Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: tumour perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum-tolerated dose of LBH589
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meaning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Turning step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stride length during turning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy of Enzalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of definite and/or suspected pneumonia cases
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting Plasma Glucose (FPG) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain level after root canal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported consecutive quit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of mean total symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of daily symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in JAK2 V617F allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Residents' Questionnaire Scores Measuring Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Residents' Cross Cultural Care Survey Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Structured Clinical Examination Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from BOMP (Bleeding on Marginal Probing) at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot and Ankle Ability Measure (FAAM) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of insufficient static and dynamic analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of ≥ Grade 2 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of patientMpower Platform
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Roentgenstereophotogrammetric analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum biomarkers of energy homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum glucose metabolism biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum adipokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients treated appropriately with respect to lipid-lowering therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of appropriate treatment among patients with high blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histological examination of a cutaneous biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Total Nasal Symptom Scores (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, nonfatal myocardial infarct (MI), and urgent target vessel revascularization (TVR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: In-hospital all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Clinical safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of recatheterization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical/Patient-Reported Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical exam findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of 90Y TARE in combination with gemcitabine and cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasomotor symptoms (VMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Blood Glucose Values Between 80 - 140
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who wear and track data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persuasive effect of using the Fitbit Charge 2 on physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: flexor and extensor cervical muscles holding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck disability questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: visual analogue scale score
Endpoint domain: Adverse events/effects